EcoR1 Capital LLC Takes $14.56 Million Position in Erasca, Inc. $ERAS

EcoR1 Capital LLC purchased a new stake in Erasca, Inc. (NASDAQ:ERAS) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 900,000 shares of the company’s stock, valued at approximately $14,562,000. Erasca accounts for 0.6% of EcoR1 Capital LLC’s investment portfolio, making the stock its 18th largest position.

A number of other institutional investors have also recently bought and sold shares of ERAS. AQR Capital Management LLC lifted its stake in Erasca by 594.8% in the 1st quarter. AQR Capital Management LLC now owns 396,202 shares of the company’s stock worth $543,000 after acquiring an additional 339,177 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Erasca by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 4,835,642 shares of the company’s stock valued at $6,143,000 after acquiring an additional 77,790 shares in the last quarter. Creative Planning increased its stake in shares of Erasca by 423.3% in the second quarter. Creative Planning now owns 244,332 shares of the company’s stock worth $310,000 after acquiring an additional 197,637 shares during the last quarter. New York State Common Retirement Fund increased its stake in shares of Erasca by 39.1% in the second quarter. New York State Common Retirement Fund now owns 37,360 shares of the company’s stock worth $47,000 after acquiring an additional 10,501 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Erasca by 51.6% during the second quarter. Invesco Ltd. now owns 172,226 shares of the company’s stock worth $219,000 after acquiring an additional 58,643 shares in the last quarter. Hedge funds and other institutional investors own 67.78% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on ERAS. Jefferies Financial Group restated a “buy” rating on shares of Erasca in a research note on Tuesday, July 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a research note on Thursday, June 11th. Mizuho dropped their price objective on Erasca from $28.00 to $26.00 and set an “outperform” rating on the stock in a report on Tuesday, May 12th. Wall Street Zen lowered shares of Erasca from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Bank of America lifted their target price on shares of Erasca from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Tuesday, July 14th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.64.

Erasca Stock Performance

Shares of ERAS stock opened at $18.87 on Tuesday. Erasca, Inc. has a 52-week low of $1.33 and a 52-week high of $24.28. The stock has a market cap of $5.87 billion, a price-to-earnings ratio of -20.29 and a beta of 0.66. The firm has a fifty day moving average of $15.61 and a 200-day moving average of $14.10.

Erasca (NASDAQ:ERAS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). On average, sell-side analysts predict that Erasca, Inc. will post -0.54 earnings per share for the current year.

Key Erasca News

Here are the key news stories impacting Erasca this week:

• Neutral Sentiment: Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek appointment as lead plaintiff. The deadline is procedural and does not determine the lawsuit’s merits. Kaplan Fox Erasca investor notice
• Negative Sentiment: A securities class action alleges that Erasca and certain executives misled investors about ERAS-0015’s competitive performance, safety profile and intellectual-property protection. Law firms cited the company’s prior claims that the drug could match a leading competitor at one-tenth the dose, had no patentability roadblocks and could be protected through 2043, followed by April disclosures of patent-infringement allegations and an admission that the comparisons were not based on head-to-head trials. Levi and Korsinsky Erasca shareholder alert
• Negative Sentiment: A large number of law firms—including Rosen, Kaplan Fox, Kahn Swick & Foti, Robbins, Hagens Berman and others—are soliciting affected investors and publicizing the case. The repeated notices increase visibility of potential litigation costs, management distraction and uncertainty surrounding Erasca’s clinical and commercial prospects, although the allegations have not been proven in court. Hagens Berman Erasca investor deadline

Erasca Company Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.